🇺🇸 glycopeptide in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 21

Most-reported reactions

1. Acute Kidney Injury — 5 reports (23.81%)
2. Off Label Use — 3 reports (14.29%)
3. Death — 2 reports (9.52%)
4. Face Oedema — 2 reports (9.52%)
5. Myelosuppression — 2 reports (9.52%)
6. Pyrexia — 2 reports (9.52%)
7. White Blood Cell Count Decreased — 2 reports (9.52%)
8. Abdominal Pain — 1 report (4.76%)
9. Acute Myeloid Leukaemia — 1 report (4.76%)
10. Anaphylactic Shock — 1 report (4.76%)

Source database →

Frequently asked questions

Is glycopeptide approved in United States?

glycopeptide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for glycopeptide in United States?

Wyeth is now a wholly owned subsidiary of Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.